{"id":"NCT00143455","sponsor":"Pfizer","briefTitle":"Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer","officialTitle":"Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-06","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2005-09-02","resultsPosted":"2010-01-21","lastUpdate":"2010-02-18"},"enrollment":485,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Carcinoma"],"interventions":[{"type":"DRUG","name":"Etoposide + cisplatin","otherNames":[]},{"type":"DRUG","name":"Irinotecan + cisplatin","otherNames":[]}],"arms":[{"label":"B","type":"EXPERIMENTAL"},{"label":"A","type":"EXPERIMENTAL"}],"summary":"To compare the effects of irinotecan hydrochloride with cisplatin to the \"standard\" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer (ED-SCLC).","primaryOutcome":{"measure":"Overall Survival (OS) for the Full Analysis Population (FAP)","timeFrame":"Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)","effectByArm":[{"arm":"Irinotecan + Cisplatin (Cohort 2)","deltaMin":10.2177,"sd":null},{"arm":"Etoposide + Cisplatin (Cohort 2)","deltaMin":9.6591,"sd":null}],"pValues":[{"comp":"OG002 vs OG003","p":"0.0556"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":67,"countries":["Austria","Belgium","Czechia","Egypt","France","Germany","Italy","Netherlands","Poland","Russia","Spain","Switzerland","Taiwan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=XRP4174D-3001&StudyName=Study%20Of%20Irinotecan%20Hydrochloride%20%28Campto%28R%29%29%20And%20Cisplatin%20Versus%20Etoposide%20And%20Cisplatin%20In%20Small%20Cell%20Lung%20Cancer"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":39},"commonTop":["Dyspnoea NOS","Fatigue","Cough","Nausea","Neutropenia"]}}